LKA-651 is under clinical development by Novartis and currently in Phase II for Diabetic Retinopathy. According to GlobalData, Phase II drugs for Diabetic Retinopathy have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LKA-651’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LKA-651 (NOV-9) is under development for the treatment of diabetic macular edema and diabetic eye diseases. It is administered intravitreally as an ophthalmic solution. LKA-651 acts as anti-erythropoietin. The therapeutic candidate is based on HuCAL (Human combinatorial antibody library) technology. It was also under development for the treatment of neovascular age-related macular degeneration, diabetic retinopathy and retinal vein occlusions.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of LKA-651’s drug-specific PTSR and LoA scores, buy the report here.